Revelation Partners is a healthcare-focused secondaries investment firm providing flexible capital and liquidity solutions—including direct secondaries, continuation vehicles, and growth equity—to the healthcare ecosystem. Headquartered in Sausalito, California, the firm manages over $2.2 billion of committed capital across all healthcare sub-sectors.
41% of their portfolio is in Healthcare. Average disclosed round size is $64.7M (across 25 rounds with reported amounts).
Portfolio
25
Fund Size
$608M
Top Stage
Series C
Last 12 Mo
1
Team
MB
Mike Boggs
Managing Partner
SH
Scott Halsted
Managing Partner
DF
Doug Fisher, MD
Partner
FL
Fred Lee
Partner
JA
Jonathan Au
Partner
RR
Rob Rein
Principal
KH
Keegan Hasson
Vice President
VV
Victoria Valverde
Healthcare Investor
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
27 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| AAspen Neuroscience | Series C | $115M | Nov 2025 |
 Arbor Biotechnologies | Series C | $73.9M | Mar 2025 |
 VitalConnect | Series F | $30M | Jan 2025 |
 Koya Medical | Series B | $26M | Nov 2023 |
 Nouscom | Series C | — | Nov 2023 |
 Nouscom Ag | Series C | — | Nov 2023 |
 Carrum Health | Series B | $45M | May 2023 |
 Entact Bio | Series A | $81M | Dec 2022 |
 Aspen Neuroscience | Series B | $147.5M | May 2022 |
 IntelyCare | Series C | $115M | Apr 2022 |
 Gravie | Series E | $75M | Mar 2022 |
 Hotspot Therapeutics | Series C | $100M | Nov 2021 |
| SSetPoint Medical Corporation | Unknown | $64M | Jan 2021 |
 SomaLogic | Series A | $214M | Dec 2020 |
 Evidation | Series D | $45M | Jul 2020 |
| EEvidation Health, Inc. | Series D | $45M | Jul 2020 |
 NeuroPace | Unknown | $67M | Jan 2020 |
| SSomaLogic, Inc. | Series A | $81M | Jan 2020 |
| VVedanta Biosciences | Series C | $16.6M | Sep 2019 |
 Providence Medical Technology | Unknown | $25M | Sep 2018 |
| EEvidation Health | Series D | $45M | Aug 2018 |
| SSPR Therapeutics | Unknown | $25M | — |
 Scorpion | Unknown | $100M | — |
 Arterys | Series C | $28M | — |
| Arterys | Series A | $12M | — |
Page 1 of 2
Top Co-Investors
B Capital4 shared
OrbiMed4 shared
EQT Life Sciences3 shared
T. Rowe Price3 shared
ARCH Venture Partners3 shared
Soleus Capital3 shared
SV Health Investors3 shared
Rethink Impact3 shared
McKesson Ventures3 shared
Logos Capital3 shared
Scale Venture Partners2 shared
Surveyor Capital2 shared
Ally Bridge Group2 shared
Lifeforce Capital2 shared
S322 shared
LYFE Capital2 shared
Frazier Life Sciences2 shared
Andera Partners2 shared
Bpifrance2 shared
Last updated: 8 September 2026